Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Other Non-Current Liabilities (2023 - 2025)

Verrica Pharmaceuticals has reported Other Non-Current Liabilities over the past 3 years, most recently at $1.8 million for Q3 2025.

  • Quarterly results put Other Non-Current Liabilities at $1.8 million for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $1.8 million (changed N/A YoY), and the annual figure for FY2024 was $2.6 million, changed.
  • Other Non-Current Liabilities for Q3 2025 was $1.8 million at Verrica Pharmaceuticals, down from $1.8 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for VRCA hit a ceiling of $2.6 million in Q4 2024 and a floor of $5000.0 in Q3 2023.
  • Median Other Non-Current Liabilities over the past 3 years was $1.8 million (2025), compared with a mean of $1.4 million.